Summary of ON101 Cream for Diabetic Foot Ulcers
ON101 cream has been found to be more effective in healing diabetic foot ulcers (DFUs) compared to standard absorbent dressings, based on a phase III clinical trial. However, its cost is higher, so it’s important to understand its economic value to make informed healthcare decisions.
Cost-Effectiveness Analysis
This study evaluated the cost-effectiveness of ON101 cream against standard dressings from the perspective of Taiwan’s healthcare system. We used data from a randomized controlled trial and Taiwan’s National Health Insurance program.
Key Findings
- Over a follow-up period of about 12.7 weeks with 236 patients, it was found that 6 patients needed to be treated with ON101 for one complete healing case.
- The cost for each complete healing case gained with ON101 was $21,128.
- This cost is below the willingness-to-pay (WTP) threshold of $32,788, indicating that ON101 is cost-effective.
- Results were particularly positive for patients with more severe ulcers and higher blood sugar levels.
Recommendations for Healthcare Providers
Given the high initial cost of ON101, its superior healing ability may justify its use, especially in patients with severe DFUs. It’s advisable to prioritize this treatment for those who are at greater risk of poor healing outcomes.
Next Steps
To implement these findings effectively:
- Define Measurable Outcomes: Set clear goals for assessing cost-effectiveness in clinics and for patients.
- Select AI Tools: Choose AI solutions that meet specific clinical needs related to wound healing.
- Implement Step by Step: Initiate a pilot project to track results using AI solutions, evaluating the impact of ON101 in real-world scenarios.
Contact for AI Solutions in Medical Management
If you’re interested in exploring AI solutions for medical management, feel free to reach out:
